ImmuPharma plc (LON:IMM – Get Free Report)’s stock price rose 37.1% during trading on Friday . The company traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.60 ($0.04). Approximately 5,829,203 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 23,045,066 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Trading Up 27.6 %
The business’s fifty day moving average is GBX 1.56 and its 200 day moving average is GBX 1.68. The company has a market cap of £13.95 million, a P/E ratio of -335.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- What is the Hang Seng index?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- How to Invest in Insurance Companies: A Guide
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
